Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-16T19:20:51.977Z Has data issue: false hasContentIssue false

Can we safely continue ADHD medication in pregnancy ?

Published online by Cambridge University Press:  31 July 2026

E. Di Giacomo*
Affiliation:
ASST Fatebenefratelli SaccoUniversity Milano Bicocca, Milan, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders, and it afflicts about 7% of young people. Its prevalence in adult women is 3.2% in the US. As a consequence, many young women might be pregnant while taking medication for ADHD, but data about safety have not yet been strictly examined. To mend such gap, a serch throug Electronic databases (PubMed,Embase,andPsycINFO) were conducted through December 31, 2023. It resulted in a meta analysis of ten studies involving 16621481 pregnant women, 30830 of them affected by ADHD. Congenital anomalies or miscarriages were not more frequent in offspring of mothers receiving treatment with methylphenidate or atomoxetine during pregnancy compared with unexposed offspring (OR, 1.14; 95% CI, 0.83-1.55; P = .41; I2 = 8% for congenital anomalies; OR, 1.15; 95% CI, 0.82-1.62, P = .67; I2 = 0% for miscarriages) or compared with the general population (OR, 1.19; 95% CI, 0.93-1.53; P = .16; I2 = 74% for congenital anomalies; OR, 0.98; 95% CI, 0.77-1.25; P = .40; I2 = 0% for miscarriage). In conclusion, evidence suggests the maintenance of methylphenidate or atomoxetine during pregnancy is safe, sincecongenital anomalies and miscarriages did not appear to significantly increase. Further studies are highlyrecommended to support and confirm these findings.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.